. M1 macrophages induce inflammatory activation and kill pathogens. In contrast, M2 macrophages suppress inflammatory activation and promote angiogenesis (Gordon, 2003) . Tumor-associated macrophages are involved in tumor angiogenesis through the production of various proangiogenic growth factors: VEGF-A, VEGF-C, EGF, TGF-β, PFGF and angiogenic chemokines (Allavena, Sica, Solinas, Porta, & Mantovani, 2008; Mantovani, Sozzani, Locati, Allavena, & Sica, 2002; Szebeni et al., 2017) . M2 macrophages show high expression of YM1, FIZZ1, Dectin-1 and scavenger receptors (Biswas, Allavena, & Mantovani, 2013; Sica et al., 2015) as well as express the hemoglobin scavenger receptor CD163 (De Vlaeminck, Gonzalez-Rascon, Goyvaerts, & Breckpot, 2016; Porta, Riboldi, Ippolito, & Sica, 2015) .
The chemokine CXCL12 (also known as SDF-1) is an important α-chemokine that binds to its receptors CXCR4 and CXCR7 (Teicher & Fricker, 2010) . CXCL12 was expressed in cancer cells or stromal cells and has been implicated in the recruitment of monocytes/macrophages and tumorigenesis (Raman, Baugher, Thu, & Richmond, 2007; Szebeni et al., 2017) . It has been shown that miR-137, miR-448 and miR-101 can directly target CXCL12 in many kinds of cancers, including papillary thyroid carcinoma, ovarian cancer and lung cancer (Dong, Jin, Li, Ren, & Liu, 2016; Lv et al., 2015; Zhang et al., 2015) . CXCL12 treatment of IGROV cancer cells induced in vitro growth, which was attributable to stimulation of DNA synthesis (Scotton et al., 2002) . Moreover, the introduction of miR-454 dramatically suppressed the migration of CXCR4 + macrophages and the ability of pancreatic ductal adenocarcinoma (PDAC) cells to form tumors via down-regulating SDF-1 (Fan et al., 2016) . More extensive studies are still required to elucidate the role of miRNAs on CXCL12 that participate in the migration and activation of immune cells in cancer. MiR-342 is located on the imprinted mouse distal 12 domain and is considered an imprinted gene candidate (Seitz et al., 2004) . Aberrant expression of miR-342 has been found in multiple cancers, and down-regulated or epigenetically silenced miR-342 expression induces some key oncogenic proteins (Dooley et al., 2017; Grady et al., 2008; Tai et al., 2015; Wang et al., 2011; Weng et al., 2016; Xie et al., 2015; Yang et al., 2016) . However, evidence of miR-342 participating in macrophage-mediated regulation of tumorigenesis remains limited. In our previous study, a murine sarcoma MS-K model can form large tumors that showed well-developed blood vessels formation Xing et al., 2016a) , and a murine osteosarcoma LM-8 can also form tumors in C3H mice (Xing et al., 2016b) . The preliminary analysis showed that blood vessel density was higher in MS-K tumor sections than in LM-8 tumor sections. Moreover, low miR-342 expression was observed in MS-K cells when compared with LM-8 cells. In the current study, we analyzed the effects of miR-342 on MS-K tumor growth, angiogenesis, and identified chemokine CXCL12 was directly regulated by miR-342 in MS-K cells. We also analyzed macrophages accumulation and TAM properties in vivo.
| RESULTS

| Inverse correlation between CD31, Cxcl12 and miR-342 in MS-K and LM-8 sarcomas
After inoculation, both MS-K and LM-8 cells formed large tumors in C3H mice (Asai et al., 1998; Sugimoto et al., 2014) . In addition, MS-K tumors showed well-developed blood vessels Xing et al., 2016a; Xu et al., 2014) . Here, we transplanted MS-K and LM-8 cells into C3H mice by subcutaneous inoculation and allowed to tumor growth for 22 days. The weight of MS-K tumors was more than that of LM-8 tumors ( Figure 1a ). Furthermore, we detected and calculated microvessel density in LM-8 tumors and compared them with MS-K tumors using anti-CD31 staining ( Figure 1b) . The results showed higher microvessel density (CD31) in MS-K tumor sections than in LM-8 tumor sections (Figure 1c ). Because increasing evidence has shown miRNAs as an important player in tumorigenesis and angiogenesis, we examined several miRNAs' expression between MS-K and LM-8 cell lines. Interestingly, the miR-342 level was found to be approximately sixfold higher in LM-8 cells than MS-K cells by quantitative real-time PCR (qPCR) (Figure 1d ). We further confirmed miR-342 expression in several primary sarcomas. qPCR analysis indicated that miR-342 was highly expressed in LM-8 tumors compared with MS-K tumors (Figure 1e ). We reported that cytokines/ chemokines, such as IL-18 and CCL-11, are important factors in angiogenesis during MS-K tumor progression (Xing et al., 2016a (Xing et al., , 2016b Xu et al., 2014) . Therefore, we analyzed some cytokine/chemokine expression between MS-K and LM-8 cells by RT-PCR and found that chemokine Cxcl12 was significantly more highly expressed in MS-K cells than in LM-8 cells (Figure 1f ). These data indicate inverse correlations of CD31, Cxcl12 and miR-342 in sarcoma cell lines, suggesting a potential regulatory relationship during tumor growth.
| Establishing and characteristics of stably over-expressed miR-342 in MS-K cells
To address the role of miR-342 in tumorigenicity and angiogenesis in MS-K tumors, we stably over-expressed miR-342 in MS-K cells. The pmR-ZsGreen1-miR-342 vector containing pre-miR-342 fragments or empty vector was constructed and transfected into parental MS-K cells, followed by antibiotic selection. Then, several ZsGreen1-positive single Genes to Cells
cells were sorted by FACSAria II to generate cell clones. These stable cell clones were termed MS-K-miR-342 or MS-K-mock cells (Figure 2a ). qPCR analysis showed that miR-342 expression in MS-K-miR-342 cell clones was higher compared with MS-K-mock cell clones (Figure 2b ). We also tried to knockdown miR-342 using a CRISPR/Cas9 tool in MS-K cells. Although the seed sequence of miR-342 in genomic DNA was successfully mutated, miR-342 level was not down-regulated significantly (data not shown). We reported that vascular endothelial growth factor, VEGF-A, was an indispensable factor for supporting cell proliferation and tumorigenesis of MS-K (Zhong et al., 2011) . We examined expression of vegf-A and vegf-C in MS-K-miR-342 and MS-K-mock cells. RT-PCR analysis showed that both vegf-A and vegf-C were highly expressed in MS-K-miR-342 cell clones and controls (Figure 2c ). Moreover, expressions of vegf-A and vegf-C were not significantly changed after miR-342 over-expression in MS-K cells, suggesting that miR-342 may not be involved in the VEGF pathway.
The growth curve assay demonstrated that cell viability was reduced in MS-K-miR-342 cl.1 and cl.4 compared with control MS-K-mock clones (Figure 2d ), suggesting a proliferation-inhibiting role of miR-342. Moreover, the colony formation assay showed that over-expression of miR-342 not only suppressed colony formation in number but also inhibited colony size development compared with the MS-Kmock clones (Figure 2e ). These results suggest that miR-342 represses cell proliferation in MS-K cells in vitro.
| CXCL12 is a direct target of miR-342
To understand the potential molecular mechanisms responsible for miR-342-induced tumor suppression, we predicted target genes of miR-342 by bioinformatic analysis using two sequence-based target prediction programs, TargetScan and miRanda. Two programs yielded a large number of possible targets of miR-342 together. The data showing that miR-342 negatively regulated tumor growth and macrophage accumulation in vivo prompted us to focus on predicted cytokine/ chemokine genes as possible miR-342 targets. Among them, chemokine CXCL12 was particularly interesting to us because CXCL12 displays angiogenic properties via binding to CXCR7 (Bonecchi et al., 2009; Lazennec & Richmond, 2010) and enhances cell growth by the CXCL12/CXCR4 Genes to Cells
axis in breast cancer and prostate cancer (Ali & Lazennec, 2007; Lazennec & Richmond, 2010; Raman et al., 2007) . Moreover, it has been shown that down-regulation of CXCL12 resulted in less CXCR4 + macrophage migration in PDAC (Fan et al., 2016) . RT-PCR analysis showed that Cxcl12 mRNA, together with its receptor Cxcr7 mRNA, was apparently down-regulated in MS-K-miR-342 cl.1, cl.3 and cl.4 compared with that in MS-K-mock cells ( Figure   3a ). However, expression of Cxcr4, another receptor of CXCL12, was not detected in any group of cells (data not shown). Western blot assays showed that CXCL12 protein levels were dramatically decreased in MS-K-miR-342 (cl.1 and cl.4) cells ( Figure 3b ). In addition, we did not detect expression of predicted miR-342 targets, such as Cxcl9, Cxcl10, Cxcl14, Ccl2, Ccl6 or Cxcr3, in any MS-K cells (data not shown). 
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To functionally validate whether miR-342 could direct regulate Cxcl12, we performed a dual-luciferase reporter assay (DLR). Sequence alignment showed that miR-342 bound to two 3'UTRs of Cxcl12 mRNA at 407 ~ 413 and 1,159 ~ 1,165 base sites (Figure 3c ). The wild-type Cxcl12-3'UTRs (~300 bp DNA), as well as synthesized mutant 3'UTRs, were cloned into the pMIR-REPORT vector. MS-Kmock cl.3 and MS-K-miR-342 cl.4 cells where miR-342 was upregulated were transiently transfected with Cxcl12-3'UTRs-wt or Cxcl12-3'UTRs-mut together with a pRT-TK Renilla vector. Moreover, MS-K-miR-342 cl.4 cells were transiently cotransfected with an empty pMIR-REPORT vector and pRT-TK Renilla vector as a control. Forty-eight hours later, the luciferase activity was detected and normalized with Renilla luciferase activity. The DLR assays showed that luciferase activity was significantly decreased after transfection with Cxcl12-3'UTR-wt #1, but not mutant Cxcl12-3'UTRmut #1 in MS-K-miR-342 cells compared with controls ( Figure 3d ). However, luciferase activity was not changed after transfection with Cxcl12-3'UTR-wt #2 or Cxcl12-3'UTR-mut #2 in MS-K-miR-342 cells compared with controls ( Figure 3e ). These results suggested that CXCL12 is a direct target of miR-342 in MS-K cells. Genes to Cells
| MiR-342 impairs MS-K cell proliferation in vitro
MS-K-mock cl.3 and MS-K-miR-342 cl.4 cells. Cell cycle analysis showed that the frequency of G0/G1 cell population of MS-K-miR-342 cl.4 cells was higher than that in control ( Figure 4b ); in contrast, the frequency of S phase cells of MS-K-miR-342 cl.4 cells was lower than that in control ( Figure 4b ). Although ratio of apoptosis cells only accounted for a fraction of cells, cell apoptosis analysis indicated an increase of apoptotic cells in MS-K-miR-342 cl.4 cells compared with that in control cells (Figure 4c,d ).
The Cxcl12 level was significantly decreased after miR-342 over-expression, accompanied by suppression of cell proliferation. To investigate whether reduced cell growth was because of Cxcl12 down-regulation by miR-342, we restored Cxcl12 expression in MS-K-miR-342 cl.4 cells and established several MS-K-miR-342/Cxcl12 cell clones. Cxcl12 expression was confirmed in cell clones by RT-PCR ( Figure  4e ). The expression of CXCL12 receptor, Cxcr7, was also restored (Figure 4e ). There was a significant increase in cell number of MS-K-miR-342/Cxcl12 cl.2, 3, 4 compared with MS-K-miR-342 cells at day 4 ~ 5 by growth curve assay ( Figure 4f ). As reported, CXCL12 could induce cancer cell in vitro growth by stimulating DNA synthesis (Scotton et al., 2002) . We found that frequency of S phase cell population was reduced in MS-K-miR-342 cells, but restored after Cxcl12 over-expression (Figure 4b ). Taken together, these result indicated that miR-342 could impair proliferation activity in MS-K cells by down-regulating chemokine Cxcl12 in vitro.
| MiR-342 inhibits tumor growth and macrophage accumulation in vivo
To evaluate the function of miR-342 on MS-K tumor growth and/or angiogenesis in vivo, stable MS-K-miR-342 cl.1, cl.4, MS-K-mock cl.1, cl.3 or parental MS-K cells were transplanted into the left and right flanks of mammary fat pads of C3H mice. The tumors were allowed to grow over 22 days. At the endpoint, the tumors were harvested and plotted (Figure 5a ). Apparent blood vessels were observed on the surface of parental MS-K tumors and MS-K-mock tumors, whereas MS-K-miR-342 tumors had smaller and less defined blood vessels (Figure 5a ). The average tumor weight was decreased approximately three times for MS-KmiR-342 cl.1 tumors and six times for MS-K-miR-342 cl.4 tumors compared with control groups (Figure 5b) . Furthermore, tumor tissues were embedded in paraffin and stained for histochemical analysis. Immunohistochemical staining showed that poor blood vessels were formed in MS-K-miR-342 cl.1 and cl.4 tumors (Figure 5c ). To quantify blood vessel density, the numbers of CD31-positive areas in tumor sections were calculated (Figure 5d ). The results showed that a significant decrease in microvessel density in MS-K-miR-342 (cl.1 or cl.4) tumor sections compared with that in controls. Jeremy J.W. et al. reported that microvessel counts were positively correlated with macrophage density in cancer (Chen et al., 2005) , and we previously found that infiltrated macrophages were crucial for regulation of blood vessel development in MS-K sarcoma (Xing et al., 2016a; Xu et al., 2014) . Therefore, we first determined macrophage accumulation between tumors formed by MS-K-miR-342 and MS-K-mock or parental MS-K cells based on CD11b expression using flow cytometry. The representative flowcharts of CD11b + cells in total tumor cells were presented (Figure 5e ). Flow cytometry analysis showed that the ratio of CD11b + cells was significantly lower in MS-K-miR-342 cl.1 and cl.4 tumors compared with that in parental MS-K tumor controls (Figure 5f ). Moreover, the total number of infiltrated CD11b + cells was also reduced MS-K-miR-342 cl.1 and cl.4 tumors ( Figure  5g ). Together, these results support our in vitro findings and suggest that macrophages might be involved in mediating the tumor-suppressive functions of miR-342 in vivo.
| Properties of tumor-infiltrated macrophages in MS-K-miR-342 tumor
In the tumor microenvironment, TAMs can produce trophic factors to trigger cancer cell proliferation, invasion and survival (Chen et al., 2005; Cho et al., 2012) . To figure out the properties of tumor-infiltrated macrophages, the CD11b (g) Total number of infiltrated CD11b + cell in tumors was calculated (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001
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markers, such as Chi3I3 and il10, did not change in the CD11b + cells of MS-K-miR-342 tumors (Supporting Information Figure S1 ). Figure 6e ). These results indicate that infiltrated macrophages in MS-K-miR-342 tumors presented less properties of proangiogenic and cell growth inducible compared with controls. Taken together, our study suggests that miR-342 regulates MS-K tumor growth via targeting chemokine CXCL12 involved in recruitment/activation of macrophages.
| DISCUSSION
MiR-342 is located within an intron of the Evl gene (Seitz et al., 2004) . It has been proposed that miR-342 might exert both anti-and protumoral functions based on expression changes and functional analysis (Dooley et al., 2017) . More often, miR-342 was reported to be a tumor suppressor by down-regulating key oncogenic pathways in various cancers. For example, miR-342 inhibited proliferation and invasion by targeting RAP2B in nonsmall lung cancer cell lines (Xie et al., 2015) . Moreover, miR-342 inhibited the proliferation of HER2-postive breast cancer cells via regulation of the HER2 pathway (Leivonen et al., 2014) and inhibited Myc activity by targeting E2F1 in breast cancer cell lines (Tai et al., 2015) . In colon cancer cell lines, miR-342 has been revealed to be a tumor suppressor by targeting NAA10 (Yang et al., 2016) and DNA methyltransferase 1 (Wang et al., 2011) . In our study, miR-342 could regulate cell proliferation, colony formation, and suppress tumor growth by directly targeting chemokine CXCL12 in MS-K cells, suggesting the tumorsuppressive capacity of miR-342 in tumorigenesis. In the present report, blood vessel density was at a high level in MS-K tumor sections compared with LM-8 tumor sections. Conversely, miR-342 was expressed less in MS-K cells than in LM-8 cells, which suggested that miR-342 might correlate with tumorigenesis and blood vessel formation. Over-expression of miR-342 in MS-K cells inhibited cell proliferation, colony formation capacity, and suppressed tumorigenicity, suggesting tumor-suppressing activity of miR-342. We have reported that VEGF-A was an indispensable factor for MS-K tumorigenesis (Zhong et al., 2011) . Nevertheless, the expressions of Vegf-A and Vegf-C were not significantly changed after over-expressed miR-342 in MS-K cells, indicating that miR-342 plays roles in molecular mechanisms other than VEGF signaling. In MS-K tumors, we evaluated the function of IL-18-induced activation of macrophages on repression of blood vessel formation (Xing et al., 2016a) . In this study, we found that over-expression of miR-342 suppressed tumor growth in vivo, accompanied by poorly developed blood vessels and significantly lower level of macrophages (CD11b + ) accumulated in MS-K-miR-342 tumors. Increasing clinical evidence of tumor cases showed that poor prognosis is associated with tumor-associated macrophage (TAM) density (Laoui, Overmeire, Baetselier, Ginderachter, & Raes, 2014) . As a main kind of noncancer cells in the tumor microenvironment, TAMs play critical roles in cell proliferation, progression, invasion and especially angiogenesis (Szebeni et al., 2017) . Therefore, miR-342 might be linked to inflammatory pathways involved in recruitment of macrophages to regulate tumor growth. It has been reported that the chemokine CXCL12 (SDF-1), together with CXCR4, was important for recruitment of CXCR4 + monocytes/macrophages into the CXCL12-rich tissue area (Szebeni et al., 2017) . SDF-1 was down-regulated by miR-454 in PDAC cells, resulting in less migration of macrophages (CD86 + ) in vitro, and macrophage density was positively correlated with high SDF-1 protein levels in vivo (Fan et al., 2016) . Of interest, the expression of Cxcl12 showed an opposite pattern to that of miR-342 in MS-K and LM-8 cells. By using a bioinformatics analysis, we confirmed that Cxcl12 was a direct target of miR-342 in MS-K cells. Furthermore, we characterized Cxcl12 as a functional target of miR-342 by RT-PCR and Western blot in stable MS-K-miR-342 cells and control cells. Because Cxcr4 was expressed in the infiltrated macrophages, we speculated that chemokine Cxcl12 was directly targeted by enhanced miR-342, which was responsible for reduced macrophage infiltration in MS-K tumors. Previous studies showed that the CXCL12/CXCR4 axis plays a critical role in proliferation and migration of tumor cells into metastatic sites in various cancers (Raman et al., 2007) . It has been reported that CXCR7 could enhance cell survival, adhesion, and increases expression of proangiogenic factors, IL-8 and VEGF, in established prostate cancer cell lines (Wang et al., 2008) . In our study, the expression of Cxcr7, but not Cxcr4, was detected in MS-K cells. Interestingly, the expression of Cxcr7 was down-regulated with over-expression of miR-342, which was consistent with the expression of Cxcl12. We presumed that the Cxcl12/Cxcr7 axis was an underlying pathway that caused miR-342 to reduce cell growth in vitro. This evidence needs to be addressed in further studies.
Tumor-associated macrophages can be induced by various extracellular signals in the tumor microenvironment to acquire the hallmarks of alternatively activated M2 macrophages. CXCL12 can drive TAM infiltration and survival under hypoxic conditions in tumors (Wang, Hong, Hsueh, & Chiang, 2012) and induce expression of CD163 and VEGF, shaping monocyte differentiation toward a proangiogenic and immunosuppressive phenotype (Sanchez-Martin et al., 2011) . Therefore, we further evaluated the properties of infiltrated macrophages derived from MS-K-miR-342 tumors by determining gene expression in the current study. Proangiogenic factors, such as Vegf-A and Thbs1, were found to be expressed less in CD11b + cells derived from MS-K-miR-342 tumors. Furthermore, the expression of the M1 macrophage marker, Cd80, was increased. Conversely, M2 macrophage markers, Cd163, Dectin1 and Ym1, were decreased in CD11b + cells derived from MS-K-miR-342 tumors compared to controls, which suggest a reduction in accumulation of alternatively activated M2 macrophages in MS-K-miR-342 tumors. We also found that Cxcl12 and Cxcr4 expression was down-regulated in TAM of MS-KmiR-342 tumors, corresponding with increased miR-342 levels, but not its host gene, Evl. Moreover, exosome markers, Cd9, Cd63 and Cd81, were detected in MS-K cells. These results suggested that Cxcl12 expression might be regulated by MS-K-miR-342 cells derived miR-342 in TAM. Our data were collected from stable MS-K cells over-expressing miR-342. We also tried to knockdown miR-342 levels to clarify its functions with a CRISPR/Cas9 tool. Unfortunately, we could not obtain stable cells where miR-342 expression was significantly down-regulated. In this work, the miR-342/CXCL12 regulatory axis was not completely analyzed because other miR-342 potential targets may affect cell proliferation, apoptosis or viability. In the future, CXCL12 rescue assay should be performed in MS-K-miR-342 cells to validate the results of the current study. In summary, this study investigated the potential role of miR-342 in tumorigenesis and its potential molecular mechanisms. The results suggested that miR-342 might play an important role in MS-K cell growth and tumor growth by directly targeting chemokine CXCL12, which caused it to control recruitment/activation of macrophages in vivo. MiR-342 as a tumor-suppressing factor might be used as a therapeutic target.
| EXPERIMENTAL PROCEDURES
| Mice
C3H/HeN mice were fed under pathogen-free condition. Eight-to 12-week-old mice were used in vivo experiments. All animal experiments were approved by Ethics Committee of Niigata University.
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| Cells and cell culture
The parental MS-K, stable miR-342-over-expressing MS-K cell clones (MS-K-miR-342) and control clones (MS-K-mock) were cultured in alpha-modified minimal essential medium (α-MEM) supplemented with 10% HS, 100 units/ml penicillin and 100 units/ml streptomycin. LM-8 cells were maintained in MEM supplemented with 10% FBS, 100 units/ml penicillin and 100 units/ml streptomycin. All of the cell lines were incubated at 37°C with 5% CO 2 .
| Plasmid construction and establishment of stable gene expressing MS-K
To stable overexpress miR-342 in MS-K cells, pmR-ZsGreen1 vector (Clontech lnc., CA, USA) was used. The fragment contained pre-miR-342 was amplified from genomic DNA of mouse bone marrow cells using primer For: CCC AAG CTT GCC TTC CAT ATC TGT ATT T; Rev: CCG GGA TCC TCT CAC TCT GCT GGT CAT, and cloned into pmRZsGreen1 vector, termed as pmR-ZsGreen1-miR-342. The inserted DNA sequences were verified by DNA sequencing. To obtain MS-K cell lines that stable expressing miR-342, MS-K cells were transfected with pmR-ZsGreen1-miR-342 or empty vector, followed by a geneticin selection (400 μg/ ml). The survived cells were subsequently sorted into 96-well plates at single cell per well by a FACSAria II system (BD, Tokyo, Japan) by ZsGreen1 expression to generate cell clones.
To rescue Cxcl12 expression in MS-K-miR-342 cells, pIRES2-EF-1α-Kurobisa Orange vector was used. The mature Cxcl12 fragment was amplified with following primer: For: CGTCAGATCCGCTAGCGCCACCATGAAACCAG TCAGC, Rev: GGAGAGGGGCGGATCCTTACTTGTT TAAAGCTTTC. The PCR product was ligated into pIRES2-EF-1α-Kurobisa Orange vector to generate pIRES2-EF-1α-KO-Cxcl12 by In-Fusion method using NEBuilder HiFi DNA Assembly Master (New England Biolabs). MS-KmiR-342 cl.4 cells were transfected with pIRES2-EF-1α-KO-Cxcl12 vector. The method to generate signal cell clones was similar to above shown.
| RT-PCR and quantitative real-time PCR (qPCR)
Total RNAs were isolated from MS-K, LM-8 cell lines and tumor-derived CD11b + cells using TRIzol reagent (Invitrogen, Carlsbad, CA) . cDNA samples were synthesized using a TOYOBO cDNA kit (TOYOBO, Osaka, Japan). The expression of related genes in MS-K cells, LM-8 cells, or MS-K-mock, MS-K-miR-342 clones was analyzed by RT-PCR. The gene expression in the tumorderived CD11b + cells was determined by quantitative real-time PCR (qPCR). Total RNAs were isolated from established MS-K-mock and MS-K-miR-342 cell clones using Trizol reagent and a Mir-X miRNA First-Strand Synthesis Kit (Clontech, Mountain View, CA). The expression of miR-342 was analyzed by using a LightCycler (Roche Diagnostics GmbH, Manheim, Germany), using snoRNA202 as a loading control. All of primers used for RT-PCR or qRT-PCR are listed in Supporting Information Table S1 .
| Cell proliferation assay
The cell clones were plated at a density of 1 × 10 4 cells per 35-mm dish (n = 3-4). The number of living cells was counted by a hemocytometer using Typan blue staining after 2, 3, 4 and 5 days.
| Colony formation assay
The MS-K-miR-342 clones were plated at 1 × 10 3 cells/35-mm dish in culture medium containing 0.8% methylcellulose. The colonies with diameter ≥100 μm were counted and calculated after 17 days.
| Western blot assay
Parental MS-K, MS-K-mock (cl.1, cl.3) or MS-K-miR-342 (cl.1, cl.4) cells were harvested and lysed. A total of 30 μg of whole protein was subjected to run a 15% SDS-PAGE and then transferred onto polyvinylidene difluoride (PVDF) membranes. The membrane was blocked with 5% nonfat milk and incubated with primary antibodies at 4°C overnight: 1/2,000 rabbit anti-CXCL12 (Abcam, Cambridge, UK), 1/50,000 rabbit anti-α-Tubulin (Cell Signaling Technology, Beverly, MA), followed by anti-rabbit IgG-HRP antibody incubation. The protein bands were detected with EzWestLumi plus solution according to the manufacturer's instructions (Cat. no. WSE-7120, Atto Corporation).
| Cell cycle analysis
The cells (MS-K, MS-K-mock cl.3, MS-K-miR-342 cl.4 and MS-K-miR-342/Cxcl12 cl.2) were collected, washed with ice-cold PBS and fixed in 70% ethanol at 4°C overnight. The fixed cells were washed, resuspended in propidium iodide (PI) solution (0.1% (v/v) Triton X-100, 10 μg/ml PI, 100 μg/ ml DNase-free RNase A) and incubated at room temperature for 1 hr at the dark. Finally, the cells were analyzed by flow cytometry (FACSAria II, BD Bioscience).
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| Cell apoptosis assay
Cell apoptosis assay was performed as previously reported (Xing et al., 2016a) . Parental MS-K, MS-K-mock cl.3 and MS-K-miR-342 cl.4 cells were washed twice with cold PBS and then made into single-cell suspensions. Cells were suspended in Annexin V binding buffer (BioLegend) at a concentration of 2 x 10 6 cells/ml. Then, 100 μL of cell suspension was transferred into a 1.5-ml tube, treated with 5 μl of PE-Annexin V (BioLegend), 5 μl of PI staining solution, and was incubated for 20 min at room temperature. Finally, the samples were suspended with another 300 μl of binding buffer, and then, the ratios of PE-and PI-positive cells were analyzed by flow cytometry (FACSAria II, BD Bioscience).
| Dual-luciferase reporter assay
Two of 3'UTR regions of Cxcl12 gene (~300 base pairs of length) containing the predicted miR-342 binding sites (407-413 and 1,159-1,165 3'UTR regions) were amplified by using following primers: For #1: GGA CTA GTC GGA AGG AAG ATC GGT GGC; Rev #1: CCC AAG CTT CCC TTC CCT AAC ACT GAC, and For #2: GGA CTA GTG CAT CTA TGT CTT GTT TGG; Rev #2: CCC AAG CTT CAC CTT TCT TTG GGC TTT GT. The 3'UTR regions were termed as CXCL12-3'-UTR-wt #1, #2, respectively. Mutated-type 3'-UTRs were synthesized and termed as Cxcl12-3'-UTR-mut #1, #2 (Integrated DNA Technologies, Japan). 3'-UTRs were cloned between Spe I and Hind III restriction sites into the pMIR-REPORT luciferase vector (Ambion, Austin, TX), to generate pMIR-Cxcl12-3'-UTRs-wt or pMIR-Cxcl12-3'-UTRs-mut vector. MS-K-miR-342 cl.4 or MS-K-mock cl.3 cells were seeded into 24-well plates and cotransfected with 0.5 μg of the pMIR-Cxcl12-3'-UTRs or empty vector and 0.05 μg of pRL-TK Renilla vector using ViaFect Transfection Reagent (Promega, USA). Forty-eight hours later, luciferase activity was measured using the dual-luciferase reporter assay system (Promega, Madison, WI) with a GloMax 20/20 luminometer (Promega, USA).
| Tumor growth assay and flow cytometry
In 1 × 10 6 of the tumor cells (parental MS-K, parental LM-8, MS-K-miR-342 clones) were implanted into the left and right flanks of C3H/HeN mice by subcutaneous injection. The mice were sacrificed, and formed tumors were removed on day 22. The tumors were prepared into single-cell suspension by mechanically cutting and digesting with collagenase (Yakurito, Tokyo, Japan), followed by incubation with allophycocyanin (APC)-labeled antimouse CD11b antibody (Biolegend, CA, USA). Then, the CD11b + cells were analyzed and sorted using a FACSAria II (BD, Tokyo, Japan).
| Hematoxylin and eosin (H&E) staining and Immunohistochemical staining
Tumors were excised from mice and fixed in Bouin's solution, embedded in paraffin blocks. Paraffin-embedded sections (4 μm) were used for examination. The rehydrated tissue sections were stained with hematoxylin and eosin (H&E) to examine microscopic morphology. CD31 expression was detected following the protocol described previously . The paraffin sections were boiled in 100 mM Tris-HCl (pH 10.0) and incubated with anti-CD31 antibody (AnaSpec, Inc., CA, USA) according to the manufacturer's instructions. The peroxidase-conjugated secondary antibody (KPL, MD, USA) and the DAB solution (VECTOR laboratories, CA, USA) were applied to detect CD31 + signals. Hematoxylin was used for the nuclear staining.
| Statistical analysis
All results are presented as the mean ± SD. For the paired statistical analysis, student's t-test was applied. In all figures, *p < 0.05, ** p < 0.01 and *** p < 0.001.
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